Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Dose escalation continues in phase II study of voreloxin in platinum-resistant ovarian cancer

Nov. 14, 2008

Antyra and Novo Nordisk sign licensing agreement for IGF antagonists

Nov. 13, 2008

HIV protease inhibitor saquinavir kills ovarian cancer cells

Nov. 13, 2008

Helion receives funding to continue development of MASP-2

Nov. 12, 2008

Marillion and Bracco sign license agreement for cancer drug 177Lu-AMBA

Nov. 12, 2008

Phase II IMC-1121B study commences in first-line treatment of NSCLC

Nov. 12, 2008

TNFerade receives FDA fast track designation for pancreatic cancer

Nov. 12, 2008

INNO-406 shows encouraging responses in phase I chronic myeloid leukemia trial

Nov. 12, 2008

Lorus completes IND-enabling studies for LOR-253

Nov. 12, 2008

Cell Therapeutics reports results from phase III trial of pixantrone in NHL

Nov. 12, 2008

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...